Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DRUP: Targeted Therapy for Advanced Cancers Based on Molecular Profiles
NCT02925234Phase 2Recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Aug 2016
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Fragment-Derived Small Molecules, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2 trial of panitumumab, olaparib, dabrafenib + trametinib, nilotinib, trametinib and 34 more, sponsored by Netherlands Cancer Institute. Started Aug 2016; status: recruiting.
02
Drugs
panitumumabolaparibdabrafenib + trametinibnilotinibtrametinib
Beyond the preview
Go deeper on NCT02925234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925234.